JP2009507896A5 - - Google Patents

Download PDF

Info

Publication number
JP2009507896A5
JP2009507896A5 JP2008530514A JP2008530514A JP2009507896A5 JP 2009507896 A5 JP2009507896 A5 JP 2009507896A5 JP 2008530514 A JP2008530514 A JP 2008530514A JP 2008530514 A JP2008530514 A JP 2008530514A JP 2009507896 A5 JP2009507896 A5 JP 2009507896A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
haloalkoxy
haloalkyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008530514A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009507896A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2006/066303 external-priority patent/WO2007031529A1/en
Publication of JP2009507896A publication Critical patent/JP2009507896A/ja
Publication of JP2009507896A5 publication Critical patent/JP2009507896A5/ja
Pending legal-status Critical Current

Links

JP2008530514A 2005-09-13 2006-09-12 ヒスタミンh4受容体活性の調節剤としての2−アミノピリミジン誘導体 Pending JP2009507896A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05380195 2005-09-13
EP06381027 2006-06-09
PCT/EP2006/066303 WO2007031529A1 (en) 2005-09-13 2006-09-12 2-aminopyrimidine derivatives as modulators of the histamine h4 receptor activity

Publications (2)

Publication Number Publication Date
JP2009507896A JP2009507896A (ja) 2009-02-26
JP2009507896A5 true JP2009507896A5 (enExample) 2009-11-05

Family

ID=37596549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008530514A Pending JP2009507896A (ja) 2005-09-13 2006-09-12 ヒスタミンh4受容体活性の調節剤としての2−アミノピリミジン誘導体

Country Status (14)

Country Link
US (1) US20090306038A1 (enExample)
EP (1) EP1928862A1 (enExample)
JP (1) JP2009507896A (enExample)
KR (1) KR20080043840A (enExample)
AR (1) AR056511A1 (enExample)
AU (1) AU2006290715A1 (enExample)
BR (1) BRPI0615880A2 (enExample)
CA (1) CA2622372A1 (enExample)
IL (1) IL189947A0 (enExample)
NO (1) NO20081003L (enExample)
PE (1) PE20070790A1 (enExample)
RU (1) RU2008114378A (enExample)
TW (1) TW200800956A (enExample)
WO (1) WO2007031529A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
CA2648036C (en) 2006-03-31 2012-05-22 Janssen Pharmaceutica N.V. Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
CL2008000467A1 (es) 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
ES2601856T3 (es) 2007-06-08 2017-02-16 Mannkind Corporation Inhibidores de la IRE-1A
US8022209B2 (en) 2007-09-12 2011-09-20 Janssen Pharmaceutica Nv Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor
PE20091035A1 (es) * 2007-11-30 2009-07-16 Palau Pharma Sa Derivados de 2-aminopirimidina
WO2009077608A1 (en) * 2007-12-19 2009-06-25 Palau Pharma, S. A. 2 -aminopyrimidine derivatives as histamine h4 antagonists
CA2709650C (en) * 2007-12-21 2016-06-07 Palau Pharma, S.A. 4-aminopyrimidine derivatives as histamine h4 receptor antagonists
EP2077263A1 (en) 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Quinazolines and related heterocyclic compounds and their therapeutic use
CN102118969B (zh) 2008-06-12 2017-03-08 詹森药业有限公司 组胺h4受体的二氨基吡啶、二氨基嘧啶和二氨基哒嗪调节剂
BRPI0915526A2 (pt) * 2008-06-12 2016-01-26 Janssen Pharmaceutica Nv uso de um antagonista da histamina h4 para o tratamento de aderências pós-operatórias
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
PE20121505A1 (es) 2009-12-23 2012-11-05 Medicis Pharmaceutical Corp Derivados de aminoalquilpirimidina como antagonistas del receptor h4 de histamina
US20120295942A1 (en) 2010-02-01 2012-11-22 Nicholas James Devereux Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
US9688989B2 (en) 2012-06-08 2017-06-27 Sensorion H4 receptor inhibitors for treating tinnitus
ES2773543T3 (es) 2013-03-06 2020-07-13 Janssen Pharmaceutica Nv Benzoimidazol-2-ilpirimidinas moduladores del receptor de histamina H4
US10125144B2 (en) 2013-10-07 2018-11-13 Kadmon Corporation, Llc Rho kinase inhibitors
EP3085700B1 (en) * 2013-12-20 2018-10-31 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China Novel piperidine carboxamide compound, preparation method, and usage thereof
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
ES2699354T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-(triazin-3-il/piridazin-3-il)-piper(-azin)idina y composiciones de las mismas para inhibir la actividad de SHP2
WO2015107493A1 (en) 2014-01-17 2015-07-23 Novartis Ag 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
JP6878316B2 (ja) 2015-06-19 2021-05-26 ノバルティス アーゲー Shp2の活性を阻害するための化合物および組成物
CN112625028B (zh) 2015-06-19 2024-10-29 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
WO2016203404A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
RU2744988C2 (ru) 2016-06-14 2021-03-17 Новартис Аг Соединения и композиции для подавления активности shp2
EP3562811B1 (en) 2016-12-29 2022-03-16 Minoryx Therapeutics S.L. Heteroaryl compounds and their use
CA3048340A1 (en) 2017-01-10 2018-07-19 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
WO2018187652A1 (en) * 2017-04-06 2018-10-11 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives as histamine h4 modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2396693A1 (en) * 1999-12-28 2001-07-05 Stephen T. Wrobleski Cytokine, especially tnf-alpha, inhibitors
EP1505064A1 (en) * 2003-08-05 2005-02-09 Bayer HealthCare AG 2-Aminopyrimidine derivatives
US20070021435A1 (en) * 2005-06-10 2007-01-25 Gaul Michael D Aminopyrimidines as kinase modulators
US20060281764A1 (en) * 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.

Similar Documents

Publication Publication Date Title
JP2009507896A5 (enExample)
JP2006524660A5 (enExample)
JP2007519649A5 (enExample)
RU2008114378A (ru) Производные 2-аминопиримидина как модуляторы активности н4-рецептора гистамина
JP2008543886A5 (enExample)
JP2014526500A5 (enExample)
JP2004516314A5 (enExample)
JP2013507425A5 (enExample)
JP2013510123A5 (enExample)
JP2013527242A5 (enExample)
JP2013510124A5 (enExample)
JP2012502037A5 (enExample)
JP2004501930A5 (enExample)
JP2010524932A5 (enExample)
JP2005526144A5 (enExample)
JP2007512299A5 (enExample)
JP2010504343A5 (enExample)
JP2010529147A5 (enExample)
JP2008501000A5 (enExample)
JP2013527243A5 (enExample)
JP2009523760A5 (enExample)
JP2010504344A5 (enExample)
JP2009518365A5 (enExample)
JP2014505107A5 (enExample)
JP2018502101A5 (enExample)